Consulting Reports

Many of the studies OHE Consulting performs are proprietary and the results are not released publicly. Studies of interest to a wide audience, however, may be made available, in whole or in part, with the client’s permission. They may be published by OHE alone, jointly with the client, or externally in scholarly publications.

The following examples of recent OHE Consulting projects are limited to those with publicly available materials that may be downloaded from this website.

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Hampson, G., Mott, D. Devlin, N. and Shah, K.

Consulting Report
January 2019

Whether or not society values curative therapies more highly (or less highly) than the sum of the iterative improvements that might come from conventional therapy has been highlighted as an important area for research. The aim of this research was thus to explore society’s preferences across curative and non-curative therapies and large and small health gains, via a discrete choice experiment.

Read more »

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Cole, A. and Towse, A.

Consulting Report
December 2018

The proliferation of health data in our ever more digitalised world of health care creates opportunities for better research around – and delivery of – pharmaceutical innovation. However, these opportunities may be constrained around the legal barriers to the use of health data for these purposes, which are poorly understood, particularly in relation to the new General Data Protection Regulation (GDPR).

Read more »

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Ferraro, J., O'Neill, P. and Towse, A.

Consulting Report
August 2018

This OHE Consulting Report reviews “Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS.” The project was funded by the ABPI.

For the year 2015/16, the Treasury reported growth in Government funded healthcare expenditure in the UK of 4.0% whilst NHS Digital reported medicines expenditure growth for the English National Health Service (NHS) for the same period at 8.0%. However, NHS Digital reported much reduced medicines expenditure growth for England of 3.5% for 2016/17, suggesting a complex underlying picture. NHS Digital growth rates are at list price as NHS Digital is not able to take account of rates of discount obtained by the NHS, which our analysis suggests are increasing, or of the rebate payments for branded drugs under the 2014-18 Pharmaceutical Price Regulation Scheme (PPRS).

It is important to stress that we are analysing data to understand trends since 2014. This work does not allow us to make any predictions about future trends.

Read more »

The Impact of New Medicines in the NHS: 70 Years of Innovation

Sampson, C., O'Neill, P. and Lorgelly, P.

Consulting Report
August 2018

In 2018, the NHS turns 70. This OHE Consulting Report demonstrates the contribution and impact of medicines to the health economy in the UK throughout the history of the NHS. Through interviews with experts we identified a shortlist of the most important medicines to have been brought to market, and from a review of the literature and evidence base we attempt to quantify the benefits of these key medicines in terms of health and economic outcomes.

Read more »

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Cubi-Molla, P., Mott, D., Shah, K., Herdman, M., Summers, Y. and Devlin, N.

Consulting Report
June 2018

Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response.

In recent critiques of economic models in this area by the National Institute for Health and Care Excellence (NICE), the idea that long-term cancer survivors (LTCS) who have received such treatments could report quality of life (QoL) scores which are similar to, or higher than, those of equivalent general population samples has not been viewed as credible. This literature review examines whether there is evidence to support the assumption that the QoL of LTCS can be similar to that of age/sex-matched population samples.

This study was funded by Roche Products Ltd.

Read more »